Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration

Synapse
Yu-Shin DingN D Volkow

Abstract

Methylphenidate (MP) (Ritalin) is widely used for the treatment of attention deficit hyperactivity disorder (ADHD). It is a chiral drug, marketed as the racemic mixture of d- and l-threo enantiomers. Our previous studies (PET and microdialysis) in humans, baboons, and rats confirm the notion that pharmacological specificity of MP resides predominantly in the d-isomer. A recent report that intraperitoneally (i.p.) administered l-threo-MP displayed potent, dose-dependent inhibition of cocaine- or apomorphine-induced locomotion in rats, raises the question of whether l-threo-MP has a similar effect when given orally. It has been speculated that l-threo-MP is poorly absorbed in humans when it is given orally because of rapid presystemic metabolism. To investigate whether l-threo-MP or its metabolites can be delivered to the brain when it is given orally, and whether l-threo-MP is pharmacologically active. PET and MicroPET studies were carried out in baboons and rats using orally delivered C-11-labeled d- and l-threo-MP ([methyl-(11)C]d-threo-MP and [methyl-(11)C]l-threo-MP). In addition, we assessed the effects of i.p. l-threo-MP on spontaneous and cocaine-stimulated locomotor activity in mice. There was a higher global uptake of c...Continue Reading

References

Apr 1, 1977·Journal of Child Psychology and Psychiatry, and Allied Disciplines·R A Barkley
Aug 1, 1992·Journal of Pharmaceutical Sciences·N R SrinivasK K Midha
Jul 1, 1991·Journal of Pharmaceutical Sciences·N R SrinivasK K Midha
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 1, 1993·Pharmaceutical Research·N R SrinivasK K Midha
Mar 3, 1998·Lancet·J M SwansonD P Cantwell
Jul 1, 1960·Toxicology and Applied Pharmacology·H SHEPPARDA J PLUMMER
May 8, 2004·CNS Spectrums·Jerrold F Rosenbaum

❮ Previous
Next ❯

Citations

Jan 5, 2007·Journal of Child and Adolescent Psychopharmacology·John S MarkowitzRafael Muniz
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Feng LiuRaul R Silva
Jun 2, 2012·Mens Sana Monographs·Avinash De Sousa, Gurvinder Kalra
Jul 20, 2005·Expert Review of Neurotherapeutics·James J McGoughRobert Suddath
Jun 9, 2005·Expert Review of Neurotherapeutics·Philip K CappCharles Conlon
Dec 22, 2007·Expert Opinion on Investigational Drugs·Lourival Baptista-NetoJoseph Gonzalez-Heydrich
Nov 10, 2009·Journal of Pain and Symptom Management·Elyse E LowerDonald Manning
Dec 25, 2007·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Natalie L LeVasseurKennerly S Patrick
Mar 21, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Donald F Smith, Steen Jakobsen
Jul 12, 2008·Environmental and Molecular Mutagenesis·Mugimane G ManjanathaSuzanne M Morris
Dec 4, 2008·Human Psychopharmacology·Kennerly S PatrickMario A González
Sep 1, 2006·Journal of Neuroscience Methods·Tracey L WheelerRobert F Smith
Apr 30, 2005·Trends in Pharmacological Sciences·Susan L Andersen
Nov 22, 2005·Expert Opinion on Drug Delivery·Kennerly S PatrickJohn S Markowitz
Feb 3, 2015·Pharmacology, Biochemistry, and Behavior·Panayotis K ThanosNora D Volkow
Dec 3, 2014·Experimental Gerontology·Shevon E BhattacharyaBarry D Waterhouse
Jun 18, 2008·Journal of Clinical Psychopharmacology·John S Markowitz, Kennerly S Patrick
Apr 17, 2017·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Sara Loureiro-VieiraJoão Paulo Capela
Jun 5, 2021·Journal of Analytical Toxicology·Christina R Smith, Madeleine J Swortwood

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.